NCCS Submits Comments in Follow-Up to FDA Patient-Focused Public Meeting
NCCS submitted comments to the Food and Drug Administration (FDA) as a follow-up to the Lung Cancer Patient-Focused Drug Development public meeting on June 28, 2013. The patient-focused drug development program is an initiative mandated by the Food and Drug Administration Safety and Innovation Act (FDASIA) and is intended to provide the agency the advice of patients […]